A Facile Supramolecular Strategy to Switch Photodynamic Pathway and Augment ROS Production of Sensitizers for Enhanced Tumor Therapy

zhiliang li,Kirk Schanze,fengling song,Ruihua Guo,Han Sun,habtom gobeze,Kanyashree Jana,yingnan wu

DOI: https://doi.org/10.26434/chemrxiv-2024-cl4pc

2024-07-02

Abstract:The photosensitizers (PSs) capable of generating radical reactive oxygen species (ROS) via the type-I electron transfer pathway under photoirradiation offer a promising solution to the challenge of unsatisfactory photodynamic therapy (PDT) in hypoxic environments. Classical PSs (type-II), however, primarily transfer excited energy to ground state O2 rather than undergoing photoinduced electron transfer, posing a tough challenge in promoting the type-I pathway through existing strategies. Herein, we demonstrate a novel and straightforward approach using bioinspired supramolecular assembly to convert classical type-II PSs into type-I supramolecular PSs with augmented ROS production. The phosphate-templated assembly facilitated the formation of nanoscale aggregates with orderly and efficient packing of PSs, effectively suppressing the energy transfer pathway by promoting photoinduced charge- separation between PSs (resulting in PS+· and PS−·), thereby enhancing the generation of superoxide radicals (O2−·) through electron transfer from PS−· to O2 (Scheme 1). Additionally, this shift of photosensitization pathway also enhances overall ROS production, overcoming the typical inhibition usually associated with PS aggregation and indicating the highly efficient ROS generation via the type-I pathway. Consequently, the type-I supramolecular PSs demonstrated excellent ROS generation capability in the treatment of hypoxic tumors, thus achieving outstanding therapeutic outcomes. This study not only addresses a critical challenge in PDT under hypoxic conditions but also opens a new avenue for modifying the sensitization behavior of clinically approved type-II PSs to achieve superior therapeutic outcomes.

Chemistry

What problem does this paper attempt to address?

This paper mainly discusses how to enhance the generation of reactive oxygen species (ROS) in tumor treatment through supramolecular strategies to transform photosensitizers (PSs) photodynamic pathways. Traditional PSs mainly transfer the excited state energy to oxygen molecules through type II pathways, but they are not effective in hypoxic environments. Researchers proposed a novel method to transform classical type II PSs into type I supramolecular PSs using bio-inspired phosphate template assembly, thereby enhancing the production of ROS, especially superoxide radicals. Through phosphate-guided assembly, PSs form ordered nanoaggregates, promoting charge separation between PSs, inhibiting energy transfer pathways, and increasing ROS production, especially superoxide radicals generated by electrons transferred from PSs anions to oxygen. This method overcomes the issue of PS aggregation commonly inhibiting ROS generation, particularly demonstrating excellent therapeutic effects in treating hypoxic tumors. This study provides a new approach to improve the behavior of clinically approved type II PSs and achieve better treatment outcomes.

A Facile Supramolecular Strategy to Switch Photodynamic Pathway and Augment ROS Production of Sensitizers for Enhanced Tumor Therapy

An Acceptor-Shielding Strategy of Photosensitizers for Enhancing the Generation Efficiency of Type I Reactive Oxygen Species and the Related Photodynamic Immunotherapy

Combining Multiple Photosensitizer Modules into One Supramolecular System for Synergetic Enhancement of Photodynamic Therapy

Mechanism research of type I reactive oxygen species conversion based on molecular and aggregate levels for tumor photodynamic therapy

Optimizing Photosensitizers with Type I and Type II ROS Generation Through Modulating Triplet Lifetime and Intersystem Crossing Efficiency

An E/Z isomer strategy of photosensitizers with tunable generation processes of reactive oxygen species

A E/Z Isomers Strategy of Photosensitizers with Tunable Generation Processes of Reactive Oxygen Species

Rational design of type-I photosensitizer molecules for mitochondrion-targeted photodynamic therapy

A Feasible Strategy of Fabricating Type I Photosensitizer for Photodynamic Therapy in Cancer Cells and Pathogens

Efficient type I and type II ROS generated aggregation-induced emission photosensitizer for mitochondria targeted photodynamic therapy

Molecular engineering to elevate reactive oxygen species generation for synergetic damage on lipid droplets and mitochondria

Deciphering Oxygen‐Independent Augmented Photodynamic Oncotherapy by Facilitating the Separation of Electron‐Hole Pairs

Activatable Type I Photosensitizer with Quenched Photosensitization Pre and Post Photodynamic Therapy.

Supramolecular Photosensitizer Enables Oxygen-Independent Generation of Hydroxyl Radicals for Photodynamic Therapy.

An unexpected strategy to alleviate hypoxia limitation of photodynamic therapy by biotinylation of photosensitizers

A Renal Clearable Nano‐Assembly with Förster Resonance Energy Transfer Amplified Superoxide Radical and Heat Generation to Overcome Hypoxia Resistance in Phototherapeutics

Type‐I photodynamic therapy induced by Pt‐coordination of type‐II photosensitizers into supramolecular complexes

Amplifying Free Radical Generation of AIE Photosensitizer with Small Singlet–Triplet Splitting for Hypoxia-Overcoming Photodynamic Therapy

Heptamethine Cyanine‐Based Nanotheranostics with Catalase‐Like Activity for Synergistic Phototherapy of Cancer

ROS-Responsive Self-activatable Photosensitizing Agent for Photodynamic-Immunotherapy of cancer

De Novo Design of Type-l Photosensitizers Agents Based on Structure-Inherent Low Triplet Energy for Hypoxia Photodynamic Therapy